HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
BIM 26226
bombesin receptor antagonist
Also Known As:
(F(5)Phe(6),Ala(11))BN(6-13)OMe; 6-F(5)Phe-11-Ala-bombesin (6-13) methyl ester; BIM-26226; BIM26226; bombesin (6-13) methyl ester, F(5)Phe(6)-Ala(11)-; bombesin (6-13) methyl ester, pentafluorophenylalanyl(6)-alanyl(11)-
Networked:
4
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones: 80400
Peptide Hormones: 1347
Bombesin: 1127
BIM 26226: 4
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Nerve Tissue Proteins: 2
Neuropeptides: 6772
Bombesin: 1127
BIM 26226: 4
Peptides: 82426
Neuropeptides: 6772
Bombesin: 1127
BIM 26226: 4
Peptide Hormones: 1347
Bombesin: 1127
BIM 26226: 4
Peptide Fragments: 373
BIM 26226: 4
Complex Mixtures: 1906
Venoms: 4328
Amphibian Venoms: 77
Bombesin: 1127
BIM 26226: 4
Biological Factors: 2472
Biological Toxins: 20
Venoms: 4328
Amphibian Venoms: 77
Bombesin: 1127
BIM 26226: 4
Related Diseases
1.
Pancreatic Neoplasms (Pancreatic Cancer)
04/17/1998 - "
Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma.
"
10/21/1994 - "
Using AR4-2J rat pancreatic carcinoma cells, the effects of a novel bombesin (BN) receptor antagonist [D-F5Phe6, D-Ala11]BN(6-13)OMe (BIM26226) on BN- or GRP-stimulated amylase release and binding of radio-labeled bombesin-like peptides to these cells were examined and compared to [D-Phe6,Leu13 psi(CH2NH)Leu14]BN(6-14) (Psi Bn(6-14)), one of the most potent BN receptor antagonists presently known.
"
2.
Gastrinoma
11/01/1996 - "
The mechanism is not known, and a potent and specific GRP-R antagonist BIM26226, which has low affinity for NMB-R, was used in vivo in athymic nude mice bearing gastrinoma subcutaneously.
"
3.
Peritoneal Neoplasms
11/01/1995 - "
In-vivo effect of somatostatin analog, lanreotide, and/or grp antagonist, bim-26226, on the growth of colon-cancer peritoneal carcinomatosis in the rat.
"
11/01/1995 - "
The effect of somatostatin analogue, lanreotide, and bombesin/GRP antagonist, BIM 26226, on the growth of colon cancer peritoneal carcinomatosis in the rat was studied.
"
4.
Neoplasms (Cancer)
11/01/1995 - "
Moreover, an up-regulation of somatostatin and bombesin receptors was observed in BIM 26226- and lanreotide-treated group tumors, respectively, Despite the presence of these specific receptors, lanreotide and BIM 26226 were inactive on tumor growth in this model.
"
5.
Colonic Neoplasms (Colon Cancer)
11/01/1995 - "
In-vivo effect of somatostatin analog, lanreotide, and/or grp antagonist, bim-26226, on the growth of colon-cancer peritoneal carcinomatosis in the rat.
"
11/01/1995 - "
injected with DHD/K12 rat colon cancer cells at day 0 and received from day 3 either lanreotide, BIM 26226, combination of treatments or peptide solvents.
"
11/01/1995 - "
The effect of somatostatin analogue, lanreotide, and bombesin/GRP antagonist, BIM 26226, on the growth of colon cancer peritoneal carcinomatosis in the rat was studied.
"
Related Drugs and Biologics
1.
Bombesin
2.
Bombesin Receptors (Bombesin Receptor)
3.
Somatostatin (Somatotropin Release-Inhibiting Factor)
4.
Peptides (Polypeptides)
5.
lanreotide (Somatuline)
6.
Gastrin-Releasing Peptide
7.
Solvents
8.
Amylases